{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [3, 5], "question": "How did the adjusted EBITDA change from 2022 to 2023 for both the Degree Program Segment and the Alternative Credential Segment?", "prediction": "Adjusted EBITDA for the Degree Program Segment increased by $34.0 million, or 19%, from $180.7 million in 2022 to $214.7 million in 2023. Adjusted EBITDA for the Alternative Credential Segment increased by $11.7 million, or 21%, from -$55.6 million in 2022 to -$43.9 million in 2023.", "ground_truth": "The adjusted EBITDA for the Degree Program Segment increased by $34 million from $180.7 million in 2022 to $214.7 million in 2023, while the Alternative Credential Segment's negative adjusted EBITDA improved by $11.7 million from -$55.6 million in 2022 to -$43.9 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [1, 4], "question": "How did the level of impairment charges for goodwill change in the Degree Program Segment and Alternative Credential Segment from 2022 to 2023?", "prediction": "The level of impairment charges for goodwill in the Degree Program Segment increased from $79.0 million in 2022 to $229.841 million in 2023. In the Alternative Credential Segment, the level of impairment charges for goodwill decreased from $78.991 million in 2022 to $149.370 million in 2023.", "ground_truth": "In the Degree Program Segment, there were no impairment charges for goodwill in either 2022 or 2023, whereas in the Alternative Credential Segment, goodwill impairment charges increased from $78.991 million in 2022 to $79.471 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [0, 3], "question": "How did Full Course Equivalent (FCE) enrollments change in both the Degree Program Segment and the Alternative Credential Segment from 2022 to 2023?", "prediction": "FCE enrollments in the Degree Program Segment decreased by 39,061, or 16.7%, from 2022 to 2023, while FCE enrollments in the Alternative Credential Segment increased by 4,284, or 4.6%, over the same period.", "ground_truth": "FCE enrollments decreased by 16.7% in the Degree Program Segment from 233,635 in 2022 to 194,574 in 2023, while they increased by 4.5% in the Alternative Credential Segment from 93,471 in 2022 to 97,647 in 2023."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 2], "question": "What were the main factors contributing to the decline in gross profit for 3D Systems Corporation in the year ended December 31, 2022, as compared to 2021?", "prediction": "The main factors contributing to the decline in gross profit for 3D Systems Corporation in the year ended December 31, 2022, as compared to 2021, were divestitures of $33.5 million, cost inflation, and supply chain pressures.", "ground_truth": "The decline in gross profit for 3D Systems Corporation in 2022 compared to 2021 was primarily due to divestitures, lower sales volumes in the dental market, and inflationary cost pressures, as indicated by the financial data provided."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [2, 5], "question": "How did the impairment charges on property and equipment and the amortization expense related to intangible assets change from 2021 to 2022?", "prediction": "The impairment charges on property and equipment decreased from $788 in 2021 to $18 in 2022. The amortization expense related to intangible assets increased from $10,469 in 2021 to $15,480 in 2022.", "ground_truth": "The impairment charges decreased from $788,000 in 2021 to $18,000 in 2022, while amortization expense increased from $10,469,000 in 2021 to $15,480,000 in 2022."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 1], "question": "How did the operating income for Healthcare Solutions and Industrial Solutions segments change from 2021 to 2022?", "prediction": "The operating income for Healthcare Solutions decreased from $69,358 in 2021 to $25,812 in 2022, a decrease of $43,546. The operating income for Industrial Solutions also decreased from $48,555 in 2021 to $22,837 in 2022, a decrease of $25,718.", "ground_truth": "The operating income for Healthcare Solutions decreased by $43.5 million from $69.4 million in 2021 to $25.9 million in 2022, while for Industrial Solutions it decreased by $25.7 million from $48.6 million in 2021 to $22.8 million in 2022."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [2, 4], "question": "How much interest income did Block, Inc. earn from customer funds in 2023, and how did it compare to the previous years?", "prediction": "$153.5 million for the year ended December 31, 2023, and it was immaterial for the years ended December 31, 2022, and 2021.", "ground_truth": "In 2023, Block, Inc. earned $153.5 million in interest income from customer funds, which was immaterial in both 2022 and 2021."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 2], "question": "How did the organizational structure change with respect to Block, Inc's management reporting in the fourth quarter of 2023 affect the allocation of BNPL platform financial results?", "prediction": "In the fourth quarter of 2023, Block, Inc. changed its management reporting structure and moved the business activities, management, and the financial results of the BNPL platform fully under the Cash App segment. As a result, the BNPL platform financial results were no longer allocated equally between the Cash App and Square segments.", "ground_truth": "In the fourth quarter of 2023, Block, Inc. changed its management reporting structure, moving the business activities and management of its BNPL platform fully under the Cash App segment, thus ceasing the previous practice of allocating 50% of revenue and gross profit from the BNPL platform to both the Square and Cash App segments."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 4], "question": "How did the classification of consumer receivables and their allowance for credit losses change from January 31, 2022 to December 31, 2023?", "prediction": "As of December 31, 2023, the amortized cost of Pass rated consumer receivables was $2.5 billion, and the amount of Classified consumer receivables was $0.1 billion. For the year ended December 31, 2023, the Company recorded a provision for credit losses of $261.3 million, and charge-offs to the allowance for credit losses were $228.8 million.", "ground_truth": "The consumer receivables classified as 'Pass' increased to $2.5 billion with $185.275 million in credit loss allowance by December 31, 2023, from the time of Afterpay's acquisition in January 2022 where the beginning allowance was $115.552 million."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [4, 5], "question": "What was the percentage change in the net property and equipment values for C.H. Robinson Worldwide, Inc. between December 31, 2022, and December 31, 2023?", "prediction": "-9.5% decrease", "ground_truth": "The net property and equipment values decreased by approximately 9.2% from $159,432,000 on December 31, 2022, to $144,718,000 on December 31, 2023."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [1, 3], "question": "What were the primary factors affecting C.H. Robinson's financial performance in 2023 as indicated in the financial statements?", "prediction": "The primary factors affecting C.H. Robinson's financial performance in 2023 included:\n\n1. Weak freight demand and excess carrier capacity in the market, leading to suppressed freight rates and decreased adjusted gross profits.\n2. Declines in both total revenues and adjusted gross profits in 2023 compared to the prior year.\n3. Decreases in average truckload linehaul cost per mile and linehaul rate charged to customers.\n4. Seasonal changes and disruptions in the transportation industry, including port congestion and the availability of transportation equipment.\n5. The COVID-19 pandemic and its impact on global demand and supply chains.\n\nThese factors resulted in a decrease in net income of 65.4% and diluted earnings per share of 63.2% compared to the prior year.", "ground_truth": "C.H. Robinson's financial performance in 2023 was primarily affected by weak freight demand and excess carrier capacity leading to reduced net income and operating cash flow, alongside declines in transportation rates."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [3, 4], "question": "How did the revenue recognition policy related to in-transit shipments change from December 31, 2022, to December 31, 2023?", "prediction": "The amount of revenue recognized for contracts where the transit period was partially complete declined significantly at December 31, 2023, compared to December 31, 2022, driven by the macroeconomic and industry factors impacting the cost of purchased transportation.", "ground_truth": "The revenue for contracts where the transit period was partially complete declined from $257.6 million at December 31, 2022, to $189.9 million at December 31, 2023, due to macroeconomic and industry factors impacting transportation costs."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 5], "question": "What was the total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, and how does it compare to the unrecognized compensation cost related to non-vested stock-based compensation arrangements as of the same date?", "prediction": "The total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, was $231,312. As of December 31, 2023, there was approximately $354.8 million of expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements.", "ground_truth": "The total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, was $231.3 million, while the expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements was approximately $354.8 million."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 4], "question": "How did the research and development expenses change from 2022 to 2023 compared to sales and marketing expenses, and what were the main reasons for these changes?", "prediction": "Research and development expenses increased by $32.5 million from 2022 to 2023, primarily due to increased personnel expenses and facility and support services. Direct research and development costs decreased by $29.0 million due to reduced enrollment in the BLUE-C clinical trial, but this was offset by increased costs related to MCED and MRD research activities.\n\nIn contrast, sales and marketing expenses decreased by $118.9 million from 2022 to 2023, primarily due to decreased direct marketing costs, professional fees, personnel expenses, and facility and support services. The decrease in direct marketing costs was driven by decreased advertising spend and the end of the promotion agreement with Pfizer Inc. in the third quarter of 2022.", "ground_truth": "Research and development expenses increased by $32.5 million due to higher personnel expenses and facility costs, while sales and marketing expenses decreased by $118.9 million primarily due to reduced marketing costs and a realignment of the sales force."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [1, 3], "question": "How did Exact Sciences Corporation’s cash and cash equivalents at the end of 2023 compare with their amount at the beginning of the year, and what was the cause of this change based on their cash flow activities?", "prediction": "Exact Sciences Corporation's cash and cash equivalents increased from $242,790 at the beginning of 2023 to $609,675 at the end of 2023. The increase was primarily due to net cash provided by operating activities ($156,119), partially offset by a net decrease in cash provided by investing activities ($88,860) and a net increase in cash provided by financing activities ($99,591).", "ground_truth": "Exact Sciences Corporation's cash and cash equivalents increased from $242.5 million at the beginning of 2023 to $605.4 million by the end of the year, driven by positive net cash provided by operating activities and an increase in net cash provided by financing activities, including proceeds from the issuance of convertible notes."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 1], "question": "How much did Esperion's net product sales increase from 2022 to 2023, and how much did their collaboration revenue increase within the same period?", "prediction": "Esperion's net product sales increased by approximately $22.4 million from $55.9 million in 2022 to $78.3 million in 2023. Their collaboration revenue increased by $18.4 million from $19.6 million in 2022 to $38.0 million in 2023.", "ground_truth": "Esperion's net product sales increased from $55.9 million in 2022 to $78.3 million in 2023, while their collaboration revenue increased from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [1, 4], "question": "How did Esperion Therapeutics, Inc.'s net loss change from 2022 to 2023 and what were the factors contributing to this change?", "prediction": "Esperion Therapeutics, Inc. reported a net loss of $233.7 million in 2022 and $209.2 million in 2023. The decrease in net loss was primarily due to increased product sales, net of $78.3 million in 2023 compared to $55.9 million in 2022, and collaboration revenue of $37.9 million in 2023 compared to $19.6 million in 2022. Additionally, research and development expenses decreased by $32.8 million in 2023 compared to 2022, and selling, general and administrative expenses increased by $33.4 million in 2023 compared to 2022.", "ground_truth": "Esperion Therapeutics, Inc.'s net loss decreased from $233.7 million in 2022 to $209.2 million in 2023, primarily due to increased net product sales and collaboration revenue, partially offset by increased selling, general, and administrative expenses."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 2], "question": "What changes occurred in the net product sales of NEXLETOL and NEXLIZET from 2022 to 2023, and how did the collaboration revenue compare during the same period?", "prediction": "The net product sales of NEXLETOL and NEXLIZET increased from $55.9 million in 2022 to $78.3 million in 2023, representing a 39.6% increase. The collaboration revenue also increased, from $19.6 million in 2022 to $38.0 million in 2023, representing a 94.4% increase.", "ground_truth": "Net product sales of NEXLETOL and NEXLIZET increased from $55.9 million in 2022 to $78.3 million in 2023, while collaboration revenue also grew from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [2, 5], "question": "What was the percentage change in the Company's total revenue from the Property & Casualty insurance vertical from 2021 to 2023, compared to the Health insurance vertical for the same period?", "prediction": "The Company's total revenue from the Property & Casualty insurance vertical decreased by 63.6% from $417,715 in 2021 to $164,234 in 2023. The Company's total revenue from the Health insurance vertical decreased by 3.1% from $176,459 in 2021 to $186,275 in 2023.", "ground_truth": "The Company's total revenue from Property & Casualty insurance vertical decreased by 60.7% from $417,715,000 in 2021 to $164,234,000 in 2023, while the Health insurance vertical saw a 5.6% increase from $176,459,000 in 2021 to $186,275,000 in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [0, 5], "question": "How did the revenue from Open Marketplace transactions compare to Private Marketplace transactions in the year ended December 31, 2023?", "prediction": "Revenue from Open Marketplace transactions was $378,730, while revenue from Private Marketplace transactions was $9,419, representing 63.8% and 2.4% of total revenue, respectively.", "ground_truth": "In the year ended December 31, 2023, Open Marketplace transactions generated $378,730,000 in revenue, which was significantly higher than Private Marketplace transactions which generated $9,419,000."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [3, 4], "question": "How did the decrease in P&C insurance revenue contribute to the overall decline in total revenue for the year ended December 31, 2023 compared to 2022?", "prediction": "The decrease in P&C insurance revenue for the year ended December 31, 2023, compared to 2022, was primarily due to a decrease in customer acquisition spending by P&C insurance carriers in response to lower-than-expected underwriting profitability, driven by higher-than-expected inflation in automobile replacement and repair costs.", "ground_truth": "The P&C insurance revenue decreased by $60.1 million in 2023, primarily due to reduced customer acquisition spending by P&C carriers, contributing significantly to the overall decline in total revenue by $70.9 million compared to 2022."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [2, 4], "question": "What are the potential effects of regulatory changes on Mind Medicine's EU operations concerning data exclusivity and medical device regulations?", "prediction": "Regulatory changes in the EU, such as the proposed revision of the EU pharmaceutical legislation, may affect Mind Medicine's EU operations concerning data exclusivity and medical device regulations. The proposal aims to reduce the eight years of data exclusivity to six years and provide additional regulatory data protection subject to specific conditions. This could impact Mind Medicine's ability to market and receive coverage for its product candidates in the EU.", "ground_truth": "Regulatory changes in the EU, such as the proposal to reduce data exclusivity from eight to six years and the MDR governing medical devices, could affect Mind Medicine's product development timelines and compliance requirements, impacting their ability to market products efficiently in the EU."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [3, 4], "question": "Between December 31, 2022, and December 31, 2023, how much of the equity securities registered under the shelf registration statement was issued by the company?", "prediction": "$99.8 million remained available for issuance under the shelf registration statement, of which $59.8 million is reserved for sales under the ATM.", "ground_truth": "Between December 31, 2022, and December 31, 2023, the company issued $0.2 million of equity securities, as the availability decreased from $100.0 million to $99.8 million."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [1, 3], "question": "What are some potential consequences mentioned in the financial statements if the company fails to comply with controlled substance laws and regulations when developing its product candidates?", "prediction": "If the company fails to comply with controlled substance laws and regulations when developing its product candidates, it may face consequences such as:\n\n* Significant fines and penalties\n* Administrative sanctions, convictions, or settlements arising from civil proceedings\n* Disgorgement of profits\n* Cessation of business activities\n* Divestiture\n* Prison time\n* Negative impact on reputation and ability to conduct business\n* Financial position, operating results, profitability, or liquidity\n* Market price of publicly traded common shares.", "ground_truth": "Failure to comply with controlled substance laws and regulations may result in increased costs, enforcement actions, regulatory scrutiny, potential litigation, and criminal prosecution, which could delay or prevent product development and commercialization."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [0, 2], "question": "What percentage of NVIDIA's total revenue for fiscal year 2024 was generated by a single customer within the Compute & Networking segment, and what challenges does this concentration pose?", "prediction": "A single customer within the Compute & Networking segment represented 13% of total revenue for fiscal year 2024. This concentration poses challenges, including the potential for significant revenue impact if the customer were to cancel or defer orders or choose to purchase from NVIDIA's competitors.", "ground_truth": "Sales to one customer, Customer A, represented 13% of total revenue for fiscal year 2024, posing challenges like potential revenue impact from losing or being unable to sell to such major customers due to trade restrictions."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 5], "question": "What was the change in NVIDIA's net income from January 29, 2023, to January 28, 2024, and how does this compare to the change in revenue for the same period?", "prediction": "NVIDIA's net income increased from $4,368 million to $29,760 million from January 29, 2023, to January 28, 2024, a change of 585.9% ($25,392 million). This compares to a revenue increase of 126% ($33,948 million) over the same period.", "ground_truth": "NVIDIA's net income increased from $4.37 billion on January 29, 2023, to $29.76 billion on January 28, 2024, while revenue increased from $26.97 billion to $60.92 billion during the same period."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 2], "question": "What percentage of NVIDIA's revenue for fiscal year 2024 came from a single customer in the Compute & Networking segment, and how does this demonstrate a risk presented in the Risk Factors?", "prediction": "According to the financial statement, sales to one customer, Customer A, represented 13% of total revenue for fiscal year 2024, which was attributable to the Compute & Networking segment. This demonstrates a risk presented in the Risk Factors, specifically the risk that a significant amount of revenue stems from a limited number of partners and distributors, and that NVIDIA may be unable to attract, retain and motivate its executives and key employees if the company is unable to maintain relationships with these customers.", "ground_truth": "In fiscal year 2024, 13% of NVIDIA's revenue came from a single customer in the Compute & Networking segment, illustrating the risk of revenue concentration from limited partners and distributors, as mentioned in the Risk Factors."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [1, 3], "question": "How did Paratek's financial position affect their ability to utilize net operating loss carryforwards after the merger, and what was the impact on regulatory operations?", "prediction": "After the merger, Paratek's net operating loss carryforwards were subject to limitations due to the ownership change. These limitations, if applied, would have restricted the use of net operating losses for up to 10 years after the merger. The company's financial position and the ownership change affected its ability to utilize net operating loss carryforwards, which could have had a material impact on regulatory operations, such as the timing and amount of future tax benefits.", "ground_truth": "Paratek's financial position was impacted by ownership changes from the merger that limited the use of net operating loss carryforwards, which could materially affect cash flow and operations as government regulations require cost compliance in various areas."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [3, 4], "question": "How did the full-year net product revenue change for Paratek Pharmaceuticals' NUZYRA from 2021 to 2022, and what was the impact on the company's net loss for the same period?", "prediction": "The full-year net product revenue for Paratek Pharmaceuticals' NUZYRA increased from $106.1 million in 2021 to $136.8 million in 2022. This increase contributed to a significant reduction in the company's net loss, with the net loss decreasing from $59.1 million in 2021 to $63.6 million in 2022.", "ground_truth": "The net product revenue for Paratek Pharmaceuticals' NUZYRA increased from $106.1 million in 2021 to $136.8 million in 2022, while the net loss increased from $59.1 million in 2021 to $63.6 million in 2022."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [0, 2], "question": "What are the factors affecting the commercialization success of NUZYRA in the U.S. as mentioned in the financial statements?", "prediction": "The commercialization success of NUZYRA in the U.S. will depend on various factors, including:\n\n* Securing sufficient starting materials and maintaining commercial manufacturing arrangements with third-party manufacturers\n* Producing, through a validated process, sufficient quantities and inventory of NUZYRA to meet demand\n* Building and maintaining internal sales, distribution, and marketing capabilities sufficient to generate commercial sales of NUZYRA, including in the community setting\n* Securing widespread acceptance of NUZYRA from physicians, healthcare payors, patients, and the medical community\n* Properly pricing and obtaining coverage and adequate reimbursement of NUZYRA by governmental authorities, private health insurers, managed care organizations, and other third-party payors\n* Maintaining compliance with ongoing FDA labeling, packaging, storage, advertising, promotion, recordkeeping, safety, and other post-marketing requirements (PMRs)\n* Managing costs and expenses commensurate with NUZYRA's projected growth\n* Establishing and maintaining collaborations with third parties for the commercialization of NUZYRA in countries outside of the U.S.", "ground_truth": "The success of NUZYRA's commercialization in the U.S. depends on securing starting materials, maintaining manufacturing arrangements, producing sufficient quantities, building sales and marketing capabilities, gaining product acceptance, obtaining sufficient reimbursement, and maintaining compliance with FDA requirements as mentioned in the financial statements."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 2], "question": "What were the factors contributing to the change in automotive sales revenue and gross margin from 2022 to 2023?", "prediction": "Automotive sales revenue increased $11.30 billion, or 17%, in 2023 compared to 2022, primarily due to a 473,382 combined Model 3 and Model Y cash deliveries. However, the average selling price on vehicles was lower due to overall price reductions year over year, sales mix, and a negative impact from the United States dollar strengthening against other foreign currencies.", "ground_truth": "Automotive sales revenue increased by $11.30 billion due to a rise in Model 3 and Model Y deliveries, while the gross margin decreased from 28.5% to 19.4% due to lower average selling prices and increased costs."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [3, 5], "question": "How did Tesla's short-term investments and inventory change from December 31, 2022, to December 31, 2023?", "prediction": "Short-term investments increased from $5,932 million to $12,696 million, and inventory decreased from $12,839 million to $13,626 million.", "ground_truth": "Tesla's short-term investments increased from $5,932 million in 2022 to $12,696 million in 2023, while inventory increased from $12,839 million in 2022 to $13,626 million in 2023."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 5], "question": "How do the commitments for capital expenditure and tax revenues in the state of New York compare to those in Shanghai, China for Tesla as of December 31, 2023?", "prediction": "As of December 31, 2023, Tesla's commitments for capital expenditure and tax revenues in the state of New York are $5.00 billion in combined capital, operational expenses, costs of goods sold and other costs in the State of New York during a 10-year period beginning April 30, 2018, with a potential \"program payment\" of $41 million to the SUNY Foundation for each year that these requirements are not met. In Shanghai, China, Tesla is required to spend RMB 14.08 billion in capital expenditures by the end of 2023, which has been achieved in 2023, and to generate RMB 2.23 billion of annual tax revenues starting at the end of 2023.", "ground_truth": "As of December 31, 2023, Tesla committed to $5 billion in combined expenditures and costs in New York state by the end of 2029, while in Shanghai, China, Tesla committed to RMB 14.08 billion in capital expenditures and RMB 2.23 billion in annual tax revenues by the end of 2023, both of which have been achieved."}
